NewsBenzingaFDA、HRR遺伝子変異を有する転移性アンドロゲン経路修飾未治療または感受性の前立腺がんに対するタラゾパリブとエンザルタミドの併用を承認 FDA、HRR遺伝子変異を有する転移性アンドロゲン経路修飾未治療または感受性の前立腺がんに対するタラゾパリブとエンザルタミドの併用を承認 Benzinga 2026.10.26 16:46 (GMT+0) Open on Benzinga Other news Ark Invest Makes Big Crypto-Related Buys Yesterday While Selling $84.8M in Nvidia Stock Abraxas Capital Closes Most of Its Hyperliquid Shorts, Account Value Down to Just $22.4 Million Nvidia Falls 35% From Record High, Short Sellers Sit on $24 Billion in Paper Profits Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory Evernorth Has Written Down Its Pre-Listing XRP Holdings by 60%
Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips
Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory